Now that AbbVie has hammered out its $55 billion takeover deal for Shire, analysts are looking for the next big biopharma tax inversion deal.
Talk about peer pressure. First, a couple of U.S. drugmakers pull off trans-Atlantic deals that shift their official HQs and lower their tax rates. Next, some bigger names go for the same tax-inversion strategy. Now, investors want to know why every drugmaker isn't jumping in.
Not every drug chief wants to ride the wave of M&A sweeping through pharma. Example: Roche CEO Severin Schwan, who says he'll stay in the shallows.
Chiltern has acquired Ockham, a fellow contract researcher, planning to absorb the company's capabilities and expand its service offerings.
Valeant, which is trying to overcome resistance from the management of Allergan for its $53 billion buyout offer, has filed a new presentation with the SEC in preparation for an investor meeting.
With a bid reaching nearly $55 billion and some goodies for the top execs, AbbVie was finally able to get Ireland-based Shire to surrender its independence, a portfolio of attention deficit hyperactivity disorder and rare disease drugs, and its low Irish tax base.
After months of semi-clandestine courtship, AbbVie and Shire have settled on a price: For $54.7 billion in cash and stock, the U.S. drugmaker will absorb its Irish target, securing a pipeline of promising rare disease treatments and a new address that should slash its tax rate.
Baxter International is riding high off promising second-quarter earnings, numbers that the company largely attributes to its 2013 acquisition of Swiss dialysis heavyweight Gambro.
Valeant may be offering $53 billion for Allergan now. But that bid might not be on the table by the time 2015 rolls around, Bill Ackman, head of Valeant takeover partner Pershing Square Capital Management, told the Botox maker's shareholders on a webcast Thursday.
Once known as a serial acquirer, Danaher broke its big acquisition drought with the addition of Siemen's clinical microbiology unit to its Beckman Coulter division. The price was not disclosed, but company officials described it as the largest deal in two years during the quarterly earnings call on the heels of the July 17 announcement.